Cadaverine Tartrate — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 CHRM1 CHRM2 CHRM3 CHRM4 ESR1 ESR2 GABRA1 GABRB1 GABRG2 GBA1 HRH1 HTR1D HTR2A OPRD1 OPRK1 OPRM1 SLC6A2 SLC6A3 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

	gene	UniProt	supporting neighbours	confidence
▸	CA4	P22748	1/20	0.37

▸	SLC22A16	Q86VW1	1/20	0.34

▸	TSHR	P16473	1/20	0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29497518	0.88	CA4 (0.46)	CA4SLC22A16
SCHEMBL30160923	0.88	CA4 (0.46)	CA4SLC22A16
Hydrochloric Acid SCHEMBL30446529	0.86	CA4 (0.45)	CA4SLC22A16
Hydrochloric Acid SCHEMBL31574660	0.86	CA4 (0.45)	CA4SLC22A16
Pyruvate SCHEMBL29497569	0.85	CA4 (0.41)	CA4
3-Hydroxybutyric Acid, (+/-)- SCHEMBL30300556	0.83	SLC22A16 (0.35)	CA4SLC22A16
Fumaric Acid SCHEMBL30455914	0.82	CA4 (0.38)	CA4TSHR
Aspartic Acid SCHEMBL30218656	0.81	GRIK1 (0.35)	CA4SLC22A16
SCHEMBL29623630	0.75	CA4 (0.38)	CA4SLC22A16
SCHEMBL30201053	0.75	CA4 (0.41)	CA4SLC22A16

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240115573-A1	Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto	UNIV EMORY (US)	2024-04-11	—	—	US	disclosed
EP-4313020-A1	MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRAL INFECTIONS AND COMPOSITIONS RELATED THERETO	Emory University (US)	2024-02-07	—	—	EP	disclosed
US-11826336-B2	Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto	EMORY UNIVERSITY (US)	2023-11-28	—	—	US	disclosed
US-20230181511-A1	METHODS OF TREATING SJÖGRENS SYNDROME	VANDERBILT UNIVERSITY	2023-06-15	—	—	US	disclosed
WO-2022204517-A1	MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRAL INFECTIONS AND COMPOSITIONS RELATED THERETO	EMORY UNIVERSITY (US)	2022-09-29	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230181511-A1	METHODS OF TREATING SJÖGRENS SYNDROME	SSB, SGMS1, SGMS2	CA4 350/4885SLC22A16 1000/4885TSHR 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.